Nebenwirkungen · Binocrit
Binocrit 1 000 IU/0.5 mL solution for injection in a pre-filled syringe Binocrit 2 000 IU/1 mL solution for injection in a pre-filled syringe Binocrit 3 000 IU/0.3 mL solution for injection in a pre-filled syringe Binocrit 4 000 IU/0.4 mL solution for injection in a pre-filled syringe Binocrit 5 000 IU/0.5 mL solution for injection in a pre-filled syringe Binocrit 6 000 IU/0.6 mL solution for injection in a pre-filled syringe Binocrit 7 000 IU/0.7 mL solution for injection in a pre-filled syringe Binocrit 8 000 IU/0.8 mL solution for injection in a pre-filled syringe Binocrit 9 000 IU/0.9 mL solution for injection in a pre-filled syringe Binocrit 10 000 IU/1 mL solution for injection in a pre-filled syringe Binocrit 20 000 IU/0.5 mL solution for injection in a pre-filled syringe Binocrit 30 000 IU/0.75 mL solution for injection in a pre-filled syringe Binocrit 40 000 IU/1 mL solution for injection in a pre-filled syringe · Abschnitt 4.8 · PDF-Seite 17
HOS-208657 · Präparat HOS-154153
Antibody-mediated pure red cell aplasia has been very rarely reported in < 1/10 000 cases per patient year after months to years of treatment with epoetin alfa (see section 4.4). More cases have been reported with subcutaneous route of administration, compared with the intravenous route.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-11T12:00:00Z · SHA-256 32f7055c1c48e53a5b1fccb28344f59f964b4cbd18912244c1595c84d77498b9 · Passage 2ae2e331292ced10fc5c499195d7f24148d69e381f25ad838dcb6c06a3918b5f · Zeichen 6003–6291 im Abschnitt